The initial signs of hepatic sinusoidal obstruction syndrome (HSOS) can be challenging to recognize in children, especially outside the hematopoietic stem cell transplantation setting. To assist clinicians to promptly identify HSOS, the European Society for Blood and Marrow Transplantation has proposed pediatric HSOS diagnostic criteria which emphasize unexplained consumptive and transfusion-refractory thrombocytopenia. To highlight the importance of these "bellwether" early signs of HSOS and the efficacy of pre-emptive treatment with defibrotide, we describe the case of a child with a right 11th rib primitive neuroectodermal tumor who developed HSOS following focal radiotherapy and actinomycin-D treatment.
INTRODUCTION
Hepatic sinusoidal obstruction syndrome (HSOS), also termed venoocclusive disease of the liver, is a life-threatening complication associated with hematopoietic stem cell transplantation (HSCT).
However, HSOS is also well described outside the HSCT setting in children with Wilms tumor, rhabdomyosarcoma, medulloblastoma, and acute lymphoblastic leukemia (ALL) treated with conventional chemotherapy containing actinomycin-D, cyclophosphamide, vincristine, 6-thioguanine, and radiotherapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] HSOS in children is associated with significant morbidity, and mortality rates range from 7% to 100%. The diagnosis of HSOS is based on two sets of guidelines known as the Baltimore and modified Seattle criteria, which have been used for the past three decades in pediatric and adult patients with HSCT (Table 1) . 10, 11 Although these criteria have only been validated in the HSCT setting, they are generally accepted and adopted in circumstances outside this context. However, these diagnostic criteria do not account for significant differences between adults and children in genetic predisposition, liver immaturity, clinical presentation, and incidence and treatment outcomes. 12 To address these differences and assist clinicians to promptly identify HSOS and intervene pre-emptively, the European Society for Blood and Marrow Transplantation (EBMT) recently has proposed a pediatric specific HSOS classification system for the diagnosis and severity of HSOS based on pediatric-specific symptoms (Table 1) . 12 In addition, data on the efficacy of pharmacological intervention for HSOS secondary to conventional chemotherapy and radiotherapy are scarce. 7 To highlight the importance of "bellwether" early warning signs of HSOS and the efficacy of pre-emptive treatment with defibrotide, we report the case of a child with a nonmetastatic right posterolateral 11th rib primitive neuroectodermal tumor (PNET) who developed recurrent mild to moderate HSOS following focal radiotherapy and actinomycin-D. Consent for publication of the case report was obtained from the parents of the patient.
RESULTS (CASE DESCRIPTION)
A 12-year-old male was diagnosed with a PNET of the right posterolateral 11th rib and was treated on the Ewing 2008 protocol (http://clinicaltrials.gov). He received six cycles of induction TA B L E 1 Diagnostic criteria for hepatic sinusoidal obstruction syndrome Modified Seattle criteria 10 The presence of at least two of the following symptoms within 20 days of HSCT:
• Hyperbilirubinemia (total bilirubin ≥ 34.2 umol/l)
• Hepatomegaly with right upper quadrant pain
• Ascites or unexplained weight gain > 2% from baseline Baltimore criteria 11 • Hyperbilirubinemia (total bilirubin ≥ 34.2 umol/l) before day 21 after HSCT
• The presence of at least two of the following symptoms:
New EBMT criteria for HSOS/VOD diagnosis in adults 18
Classical HSOS/VOD Late onset HSOS/VOD
In the first 21 days after HSCT >21 days after HSCT
• Bilirubin ⩾2 mg/dl (or 34 umol/l)
• The presence of two of the following criteria must be present:
○ Ascites
• Classical VOD/HSOS beyond day 21 OR
• Histologically proven HSOS/VOD OR
• The presence of two or more of the following criteria must be present: 
DISCUSSION
The incidence of HSOS in children outside the HSCT setting has been reported to range between 1.2% to 8% for Wilms tumor, 12% for patients with ALL, and 1.2-5.3% for rhabdomyosarcoma; moreover, there are several case reports of children with medulloblastoma. 4, 5, 8, 9 There is a single case report of HSOS in recurrent yolk sac tumor, primary central nervous system lymphoma, idiopathic pulmonary hemosiderosis with autoimmune thrombocytopenia, and paraspinal PNET. [14] [15] [16] [17] The standardized Baltimore and modified Seattle criteria allow diagnosis of HSOS with good specificity (89% and 95%, respectively) but low sensitivity (56%). 5, 12 This is exemplified by a report following a single-center retrospective study of 91 patients with Wilms tumor, who had undergone liver biopsy during nephrectomy after preoperative chemotherapy; 41 patients (45.1%) had histological evidence of HSOS but only 12 (13.2%) of them were clinically diagnosed with HSOS based on Seattle criteria. 6 Hence, identification of more sensitive markers is critical to make an earlier diagnosis of HSOS. The use of clinical risk factors associated with HSOS, such as young age (<2 years old), previous radiotherapy ≥12 Gy, low body weight, and right-sided tumors may assist with the identification of at risk patients. 8, 18 The onset of HSOS following conventional chemotherapy is acute with a sudden drop in platelet count, elevated liver enzymes, and coagulopathy, classically after the second to sixth dose of actinomycin-D, occurring 7-14 days after the last dose. 7 Traditionally, severe thrombocytopenia was not included in the diagnostic criteria for HSOS.
In one case series of Wilms tumor, isolated severe thrombocytopenia was the most striking earliest sign with a median platelet count of 12 × 10 9 /l (range 4-48 × 10 9 /l) before signs of HSOS became evident. 3 Others have also reported this observation in patients with
Wilms tumor and proposed naming it "hepatopathy-thrombocytopenia syndrome." 1, 2 The authors concluded that children developing "isolated" thrombocytopenia following actinomycin-D are "at risk" of developing HSOS, which, given the liver biopsy findings, is unlikely to be related to the immune-mediated effect of actinomycin-D. 19 In another study, 12% of patients with ALL had severe persistent thrombocytopenia out of proportion with the degree of neutropenia and thought to be the sentinel clue for 6-thioguanine induced HSOS. 4 The current understanding of HSOS pathophysiology emphasizes that consumptive thrombocytopenia and refractoriness to platelet transfusions secondary to uncontrolled endothelial/sinusoidal activation is the hallmark of HSOS. 12 Based on this, the EBMT has proposed that unexplained consumptive and transfusion-refractory thrombocytopenia be included as one of the diagnostic criteria for HSOS in children and be prospectively validated in clinical trials. 12 In our case, severe isolated thrombocytopenia was the earliest sign Supportive care measures using blood products, sodium restriction, and diuretics remain the cornerstone in the management of HSOS. 7 Treatment strategies using a number of different drugs, including heparin, antithrombin, recombinant human tissue plasminogen activator, N-acetylcysteine, protein C concentrate, gabexate mesylate, and high-dose methylprednisolone alone or in combination have demonstrated variable success and made no difference in outcome compared to defibrotide alone. 5, 7, 9, 15, 20 Defibrotide modulates platelet activity, promotes fibrinolysis, decreases thrombin generation and activity, and reduces the circulating levels of plasminogen activator inhibitor type 1. Defibrotide lacks systemic anticoagulant activity, and severe hemorrhage or serious toxicities have not been reported in the literature. 21, 22 In both HSCT and non-HSCT settings, HSOS has been effectively treated with defibrotide, using a dose of 25 mg/kg/day in the majority of cases. 13, 21, 22 Our patient was pre-emptively treated with defibrotide using doses between 25 and 40 mg/kg/day. This early "pre-emptive" treatment with defibrotide successfully attenuated the progression to severe HSOS.
In summary, our case highlights three important points. The first is the potential for development of HSOS in patients with PNET treated on therapeutic regimens with radiotherapy involving the right side of the body, with liver exposure when combined with actinomycin-D. Secondly, the importance of severe isolated thrombocytopenia refractory to platelet transfusions in a patient should flag a diagnosis of early or mild HSOS. Thirdly, the efficacy of pre-emptive treatment with defibrotide has been highlighted. Based on our case report, we recommend regular monitoring of platelet counts and liver function tests in patients at risk of HSOS for early identification of milder cases. Consideration should be given to pre-emptive treatment using defibrotide.
